Online Only Articles

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria
Dokuz Eylul University, Izmir, Turkey
Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
Tennessee Oncology, Chattanooga, TN, USA
North Shore Hospital, Auckland, New Zealand
Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Norton Cancer Institute, Louisville, KY, USA
Princess Alexandra Hospital, Brisbane, Australia
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Janssen Ltd, High Wycombe, UK
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Barts Cancer Institute, Queen Mary University of London, London, UK
Vol. 105 No. 4 (2020): April, 2020 https://doi.org/10.3324/haematol.2019.223743